RT Journal Article
SR Electronic
T1 Dietary Exposure to Oxidized Lipids in US Infants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.22.22276754
DO 10.1101/2022.06.22.22276754
A1 Lisaura Maldonado-Pereira
A1 Kristin Isaacs
A1 Carlo Barnaba
A1 Ilce Gabriela Medina-Meza
YR 2022
UL http://medrxiv.org/content/early/2022/06/22/2022.06.22.22276754.abstract
AB Baby Foods (BFs) and Infant formulas (IFs) are the main sources of nutrition for an infant throughout the 1st year of life. A variety of enriched products are commercially available for parents seeking to fulfill their baby’s nutritional needs. Consequently, different bioactive lipids are present in BFs and IFs including dietary oxidative substances (DOxS) whose known toxicity has been associated with mutagenicity, cancer, and other chronic diseases. In this work, we performed an exposure assessment of 25 bioactive lipids on a total of 63 baby food samples (50 – IFs and 13 – BFs) commercially available in the US. To determine the dietary exposure to DOxS, we used EPA’s SHEDS-HT probabilistic model. Even though β-Sitosterol was the most exposed bioactive lipid with 75,4 µg/day, cholesterol was the most absorbed compound during the entire first year (19,320 µg/day). Additionally, we found 7α-hydroxycholesterol (7α-OH) as a potential DOxS biomarker of the BFs manufacturing process. This is the first time that an exposure assessment including DOxS ingested by infants after BFs and IFs consumption is performed, enabling much-needed information regarding these hazardous compounds and their potential effects on infants’ health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funding by the Center for Research Ingredients Safety (CRIS) with the GR100229 grant, the USDA National Institute of Food and Agriculture, Hatch project MICL02526 to I.G.M.M.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors